

**ONE HUNDRED FIFTH LEGISLATURE - FIRST SESSION - 2017**  
**COMMITTEE STATEMENT**  
**LB401**

---

**Hearing Date:** Thursday February 02, 2017  
**Committee On:** Health and Human Services  
**Introducer:** Hilkemann  
**One Liner:** Change provisions relating to metabolic screening

---

**Roll Call Vote - Final Committee Action:**  
Advanced to General File

---

**Vote Results:**

<b>Aye:</b>	6	Senators Crawford, Erdman, Howard, Kolterman, Linehan, Williams
<b>Nay:</b>	1	Senator Riepe
<b>Absent:</b>		
<b>Present Not Voting:</b>		

---

**Verbal Testimony:**

**Proponents:**

Senator Robert Hilkemann  
Dr. William Rizzo  
Meghan Korth  
Jeff Swanson  
Shannon Butalla  
Ashlee Springer

**Representing:**

Introducer  
Self  
Self  
Self  
Self  
Self

**Opponents:**

**Representing:**

**Neutral:**

**Representing:**

---

**Summary of purpose and/or changes:**

LB 401 adds X-linked adrenoleukodystrophy (X-ALD), mucopolysaccharidoses type 1 (MPS-1), and Pompe disease to the required newborn screening program.

**SECTION BY SECTION:**

Section 1: Amends Section 71-519 to add X-linked adrenoleukodystrophy (X-ALD), mucopolysaccharidoses type 1 (MPS-1), and Pompe disease to mandated newborn screening. Adds X-linked adrenoleukodystrophy (X-ALD), mucopolysaccharidoses type 1 (MPS-1), and Pompe disease to dietary and therapeutic management to be responsibility of parent.

Section 2: Repeals Section 71-519.

---

